Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Operating Leases (2019 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 7 years of Operating Leases data on record, last reported at $1.4 million in Q1 2025.

  • For Q1 2025, Operating Leases fell 71.78% year-over-year to $1.4 million; the TTM value through Feb 2025 reached $1.4 million, down 71.78%, while the annual FY2024 figure was $1.7 million, 82.19% down from the prior year.
  • Operating Leases reached $1.4 million in Q1 2025 per LFCR's latest filing, down from $7.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $24.4 million in Q1 2021 and bottomed at $1.4 million in Q1 2025.
  • Average Operating Leases over 5 years is $9.5 million, with a median of $9.3 million recorded in 2023.
  • Peak YoY movement for Operating Leases: skyrocketed 34.0% in 2023, then plummeted 82.19% in 2024.
  • A 5-year view of Operating Leases shows it stood at $11.3 million in 2021, then plummeted by 38.12% to $7.0 million in 2022, then skyrocketed by 32.96% to $9.3 million in 2023, then decreased by 20.47% to $7.4 million in 2024, then tumbled by 80.65% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $1.4 million in Q1 2025, $7.4 million in Q4 2024, and $4.8 million in Q3 2024.